Phenotypic Discovery of Triazolo[1,5‑c]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype

Phenotypic drug discovery (PDD) continues to fuel the research and development pipelines with first-in-class therapeutic modalities, but success rates critically depend on the quality of the underlying model system. Here, we employed a stem cell-based approach for the target-agnostic, yet pathway-ce...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2022-11, Vol.65 (22), p.15263-15281
Hauptverfasser:	Wesseler, Fabian, Lohmann, Stefan, Riege, Daniel, Halver, Jonas, Roth, Aileen, Pichlo, Christian, Weber, Sabrina, Takamiya, Masanari, Müller, Eva, Ketzel, Jana, Flegel, Jana, Gihring, Adrian, Rastegar, Sepand, Bertrand, Jessica, Baumann, Ulrich, Knippschild, Uwe, Peifer, Christian, Sievers, Sonja, Waldmann, Herbert, Schade, Dennis
Format:	Artikel
Sprache:	eng
Schlagworte:	Bone Morphogenetic Protein 2 - metabolism Bone Morphogenetic Proteins - drug effects Bone Morphogenetic Proteins - metabolism Cell Differentiation Osteogenesis Quinazolines - pharmacology Smad Proteins - metabolism Triazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!